GMED, US3795772082

RBC cuts target to USD 85.00 for Globus Medical stock

Published on 10/15/2026 at 18:33 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Revenue was USD 789.61 million in the second quarter. Globus Medical stock costs EUR 69.95 on October 15, 2026, up 2.89 percent on Nasdaq.

Target revision shapes valuation

On October 1, 2026, RBC Capital lowered its target from USD 115.00 to USD 85.00.
Adjusted earnings per share reached USD 1.34 in the second quarter, with full-year guidance of USD 4.95-5.05.
Globus Medical stock costs EUR 69.95 at Lang & Schwarz on October 15, 2026 at 6:30 p.m. CEST, 2.89 percent above the prior close on Nasdaq of October 14, 2026.
Globus Medical will announce third-quarter results on November 5, 2026.

GMED, US3795772082, Illustration mit AI erstellt.

RBC Capital analyst Shagun Singh lowered the price target for Globus Medical from USD 115.00 to USD 85.00 on October 1, 2026, while retaining an Outperform rating, according to Markets Insider. The new target is 8.25 percent above the USD 78.52 Nasdaq price. At Lang & Schwarz, Globus Medical stock stood at EUR 69.95 on October 15, 2026 at 6:30 p.m. CEST, while the Nasdaq quote was up 2.89 percent versus the prior close of October 14, 2026.

Second-quarter figures set the baseline

Globus Medical generated USD 789.61 million in revenue in the second quarter ended June 30, 2026. Yahoo Finance reported adjusted earnings per share of USD 1.34 and full-year adjusted earnings-per-share guidance of USD 4.95-5.05 on October 8, 2026, with the company’s revenue guidance unchanged.

Stock sits below its yearly high

The Nasdaq price of USD 78.52 at 12:32 p.m. ET on October 15, 2026 stood 22.56 percent below the 52-week high of USD 101.40 and 34.62 percent above the 52-week low of USD 58.32. Trading volume was 479,276 shares, against an average volume of 1,447,734 shares, on October 15, 2026.

Valuation and the next reporting date

Globus Medical had a market capitalization of USD 10.5 billion, a trailing P/E ratio of 20.15 and a 52-week range of USD 58.32 to USD 101.40 as of October 15, 2026. The company will announce results for the third quarter ended September 30, 2026 after the market close on November 5, 2026, according to Markets Insider.

Comparison with peers

Globus Medical (NYSE, USD): plus 2.89 percent, P/E 20.15, market capitalization USD 10.5 billion.
Stryker (NYSE, USD): plus 3.31 percent, P/E 30.12, market capitalization USD 111.6 billion.
Zimmer Biomet (NYSE, USD): plus 2.37 percent, P/E 22.82, market capitalization USD 17.9 billion.

Euro quote after the Xetra close

The euro quotation places the stock at EUR 69.95 at Lang & Schwarz on October 15, 2026 at 6:30 p.m. CEST. The Nasdaq session supplied the same-day comparison, with USD 78.52 up 2.89 percent from USD 76.31 on October 14, 2026. The further course of trading is shown by the continuously updated real-time quote of Globus Medical stock.